- Home
- CORT
as 05-30-2025 4:00pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 7.1B | IPO Year: | N/A |
| Target Price: | $142.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.14 | EPS Growth: | 8.36 |
| 52 Week Low/High: | $28.04 - $117.33 | Next Earning Date: | 05-05-2025 |
| Revenue: | $685,446,000 | Revenue Growth: | 30.93% |
| Revenue Growth (this year): | 35.85% | Revenue Growth (next year): | 35.22% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Robb Gary Charles | CORT | Chief Business Officer | May 20 '25 | Sell | $75.85 | 2,279 | $172,862.15 | 16,586 | |
| Guyer William | CORT | Chief Development Officer | May 16 '25 | Sell | $74.17 | 32,262 | $2,393,014.49 | 5,487 | |
| Guyer William | CORT | Chief Development Officer | May 6 '25 | Sell | $74.31 | 7,060 | $524,652.60 | 5,487 | |
| Lyon Joseph Douglas | CORT | See Remarks | May 1 '25 | Sell | $71.96 | 9,350 | $672,781.12 | 9,009 | |
| Maduck Sean | CORT | See Remarks | May 1 '25 | Sell | $72.37 | 39,410 | $2,842,769.23 | 85,622 | |
| Swisher Daniel N JR | CORT | Director | Apr 10 '25 | Sell | $70.22 | 2,200 | $154,484.00 | 0 | |
| Guyer William | CORT | Chief Development Officer | Apr 1 '25 | Sell | $114.51 | 678 | $77,639.00 | 5,487 | |
| Lyon Joseph Douglas | CORT | See Remarks | Mar 31 '25 | Sell | $104.65 | 200,650 | $20,167,953.55 | 9,009 | |
| Maduck Sean | CORT | See Remarks | Mar 31 '25 | Sell | $104.60 | 100,590 | $10,121,593.92 | 85,622 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Mar 31 '25 | Sell | $104.72 | 35,452 | $3,365,009.94 | 2,981,985 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
New Strong Sell Stocks for May 29th
StockStory
6 days ago
1 Growth Stock with All-Star Potential and 2 to Avoid
Simply Wall St.
9 days ago
Discover 3 Growth Stocks With Insider Ownership Up To 28%
StockStory
10 days ago
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)
MT Newswires
11 days ago
Corcept Therapeutics Insider Sold Shares Worth $2,030,453, According to a Recent SEC Filing
MT Newswires
11 days ago
Corcept Therapeutics Insider Sold Shares Worth $2,393,014, According to a Recent SEC Filing
Argus Research
11 days ago
CORT: Raising target price to $84.00
StockStory
13 days ago
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.